Analytics

The report mentions the following key events and results:

• Medtronic acquired Covidien for US $50 bn. The transaction displaced Johnson & Johnson as the medtech industry leader. The deal amount accounts for the majority of medtech M&A market value of US $83 bn in the first six months of this year. Market value exceeded…

The court ruling contains a clause that drug promotion for off-label use must be supported by clinical evidence and cannot be false or misleading. Amarin’s product Vasepa (icosapent ethyl) is a synthetic derivative of an omega-3 EPA. It is prescribed to patients with severe triglyceridemia (blood levels of triglycerides of 500…

R-pharm will be receiving 500 million rubles for oncology and bone disorder drug APIs. Rusnano ‘s subsidiary NEVZ-Ceramics plans to spend a 150 million ruble loan on manufacturing bioceramic implants. Two other pharmaceutical companies on the list of recipients are Pharmasyntez with a 300 million rubles loan and Nearmedic with…

Retail pharmacy sales gained 22.4% to a total of 386 billion rubles and thus outperformed all other market segments. Volume growth was a much more modest 1.9% to a total of 2.1 billion packs sold in the first two quarters. Average price increase was 6.5%. The real cost to consumer, however, grew 20% due to the continuing ruble…

The deal marks the entry of the third largest pharmaceutical company in India into Russia. Lupin is also the third largest supplier of generics to the US. Generics manufacturer Biokom was founded in 1991. Its turnover reached 861.2 million rubles in 2014, according to Lupin.

Sources: http.//www.lupin.com, Pharmvestnik,…

80% of respondents plan to continue with their business development plans in Russia despite the unstable economic and political situation. 25% of study participants plan to launch new products. One third of those surveyed consider localization of manufacturing as an opportunity to improve company finances in the conditions of ruble…

Both foreign and Russian companies continue to invest actively into the sector, which has already translated into a 10–15% annual growth rate despite economic difficulties. President’s Order on providing 90% of the Essential Drug List with domestic drugs by 2020 may be executed before the deadline. 67% are already manufactured…

The global prescription drug market should reach 1 billion USD in 2020 (2014–2020 CAGR: 4.8%)...